Objective:To study expression of Galectin-1 and Galectin-9 in ovarian epithelial carcinoma and the relation between the expression and parameters of clinical pathology.Methods:Collected from February 2013 to December 2016 in Shengjing Hospital by surgical therapy and confirmed by pathology of ovarian epithelial carcinoma 38 cases,border ovarian tumor 7 cases,and benign tumor 9 cases.SP immunohistochemical method is applied to detect the expression in benign ovarian tumor, border ovarian tumor and ovarian epithelial carcinoma, and the relationship between the expression of Galectin-1 and Galectin-9 and parameters of clinical pathology.Results:The expression of Galectin-1 in ovarian epithelial carcinoma tissue (86.84％) was significantly higher than benign ovarian tumor (11.11％), the expressions of Galectin-1 in the benign ovarian tumor and the other two tissues have significantly differences(P ＜ 0.05), the differences have the statistically significance, but the expressions of Galectin-1 in the ovarian epithelial carcinoma and border ovarian tumor have no obvious differences (P ＞ 0.05), the relation between the expression of Galectin-1 in ovarian epithelial carcinoma and patients'age,pathological type, differentiation degree and lymph node metastasis has no obvious correlation(P ＞ 0.05),but FIGO staging(P ＜0.05).The expression of Galectin-9 in benign ovarian tumor(100％) was significantly higher than ovarian epithelial carcinoma(65.79％) and borden ovarian tumor(85.71％), the expressions of Galectin-9 in the ovarian epithelial carcinoma and benign ovarian tumor have significantly differences(P ＜ 0.05), the differences have the statistically significance, but the expressions of Galectin-9 in the border ovarian tumor and the other two tissues have no obvious differences (P ＞ 0.05), the relation between the expression of Galectin-9 in ovarian epithelial carcinoma and patients'age, pathological type,differentiation degree and FIGO staging has no obvious correlation (P ＞ 0.05), but lymph node metastasis (P ＜ 0.05).Conclusion:Galectin-1 and Galectin-9 will be used as the new tumor marker to provide the relative evidence for diagnosis and prognosis of ovarian carcinoma.%目的:研究半乳糖凝集素-1(Galectin-1)和半乳糖凝集素-9(Galectin-9)在卵巢上皮癌中的表达及与临床病理参数间的关系.方法:收集2013年2月至2016年12月就诊于盛京医院行手术治疗并经病理证实的卵巢上皮癌38例、卵巢交界性肿瘤7例及卵巢良性肿瘤9例.应用SP免疫组化方法检测Galectin-1和Galectin-9在卵巢良性肿瘤、交界性肿瘤及卵巢上皮癌中的表达,并分析卵巢上皮癌组织中的Galectin-1和Galectin-9的表达与卵巢上皮癌的临床病理参数间的关系.结果:Galectin-1在卵巢上皮癌组织中的表达(86.84％)及卵巢交界性肿瘤(85.71％)中的表达明显高于卵巢良性肿瘤(11.11％),且两者与卵巢良性肿瘤之间有明显差异,具有统计学意义(P＜0.05);而卵巢上皮癌与卵巢交界性肿瘤之间无明显差异(P＞0.05).Galectin-1在卵巢上皮癌中的表达水平与卵巢上皮癌患者的年龄、病理类型、分化程度及淋巴结转移无明显相关(P＞0.05),而与卵巢上皮癌的FIGO分期有关(P＜0.05).Galectin-9在卵巢良性肿瘤组织中的表达(100％)明显高于卵巢交界性肿瘤(85.71％)及卵巢上皮癌(65.79％),且卵巢上皮癌与卵巢良性肿瘤之间有明显差异,具有统计学意义(P＜0.05),而卵巢交界性肿瘤与其他两者之间无明显差异(P＞0.05).Galectin-9在卵巢上皮癌中的表达水平与卵巢上皮癌患者的年龄、FIGO分期、分化程度及病理类型无关(P＞0.05),而与卵巢上皮癌的淋巴结转移有关(P＜0.05).结论:Galectin-1和Galectin-9均可望成为新的肿瘤标记物,为卵巢癌的诊断和预后提供相关证据.
展开▼
